A brief conference update from Topf with a slide photo as Tuttle begins her GLP-1 talk. Little detail beyond the image.
Recap by typeshit. Post by Joel M. Topf, MD FACP on X.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
Women on CagriSema hit 20% weight loss far more often than on semaglutide alone, 68.7% vs 38.0%, though Novo calls the comparisons exploratory.
Joshi delivered the ThaneVashi Oration in Nashik, focused on nutritional considerations for people on GLP-1 treatment.
Loading…